Molsidomine
Trade name: motazomin
Small moleculeexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
1
Earliest trial started Feb 1, 1992 (NCT00382421)
Timeline
No events for the selected filters.
Indications
Approved for
Mechanism of action
- Nitric oxide synthaseACTIVATOR
Nitric oxide synthase activator
Chemistry & pharmacology
Loading structure…
SMILES
CCOC(=O)[N-]c1c[n+](N2CCOCC2)no1- Mol. weight
- 242.24 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Prodrug
Sources
- ChEMBLCHEMBL1329455 ↗
- ChEMBLCHEMBL1256353 ↗
Also known as
- cas 276
- cas 276
- corvasal
- corvasal
- corvasal
- corvaton
- corvaton
- corvaton mite
- corvaton ret
- molsidolat
- molsidomin
- molsidomine
- molsidomine
- molsidomine
- molsidomine
- molsidomine
- molsidomine
- molsidomine
- molsidomine
- morsydomine
- morsydomine
- morsydomine
- motazomin
- n-morpholino sydnonimine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01363661 | Phase 4 | Jun 1, 2011 | Onze Lieve Vrouw Hospital, Therabel Pharma SA/NV |
| NCT00382421 | N/A | Feb 1, 1992 | Hospital Lucerne, Luzerner Kantonsspital |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Hospital Lucerne | Academic/Hospital | 1 | 0 | 1 | 1992 |
| Luzerner Kantonsspital | Academic/Hospital | 1 | 1 | 1 | 1992 |
| Onze Lieve Vrouw Hospital | Academic/Hospital | 1 | 0 | 1 | 2011 |
| Therabel Pharma SA/NV | For profit | 1 | 1 | 1 | 2011 |
4 organizations
Page 1 / 1